BMC Medicine Time to First Decision: 8-14 Weeks Median

BMC Medicine uses Editorial Manager (Aries Systems). The visible status labels reflect BMC's editorial pipeline:

"With Editor" is the initial-screen stage. The handling Editor checks scope fit (BMC Medicine prioritizes broad-relevance medical research), reporting-guideline compliance (CONSORT for RCTs, STROBE for observational studies, PRISMA for systematic reviews, ARRIVE for animal studies), and ethical-approval documentation. Roughly 40-50% of BMC Medicine submissions are desk-rejected at this stage, primarily for scope mismatch or insufficient reporting-checklist completion.

"Under Review" means the paper has passed editorial assessment and is with two or three peer reviewers. BMC Medicine typically aims for two reviewers; complex methodological papers may have three. If first-choice reviewers decline, recruitment can extend the wait by 1-2 weeks.

"Reviews Completed" means the reviewer reports have arrived and the Editor is weighing them. This is usually a short stage (1-2 weeks).

"Decision in Process" means the Editor has decided and the formal decision letter is being prepared. This is days, not weeks.

If your paper sits at "With Editor" for more than 3 weeks, the most likely explanation is Editor workload or routing to an Associate Editor. After 4 weeks at "With Editor", a polite inquiry is appropriate.

Three structural factors drive the timeline:

Reporting-guideline compliance checks. BMC Medicine, as part of the BMC Series, requires strict reporting-guideline compliance. Editors check CONSORT, PRISMA, STROBE, ARRIVE, and other relevant checklists before assigning reviewers. Papers that complete checklists with "see Methods" or "N/A" generate editorial returns at this stage, adding 1-2 weeks before peer review begins.

Reviewer recruitment for clinical specificity. BMC Medicine covers all of clinical medicine plus public health and global health. Reviewer pools for narrower subfields (e.g., specific tropical diseases, rare cancers, niche preventive interventions) can require 3-4 weeks of recruitment. About 20% of BMC Medicine submissions experience reviewer-recruitment delays.

Open-access editorial volume. BMC Medicine processes high submission volume relative to its editorial capacity. The handling-Editor model scales reasonably, but high-volume periods (post-conference cycles, January submissions) push the initial-screen wait from 1 week to 3 weeks.

If your paper has been at "Under Review" for 6-10 weeks, that is normal. The more useful calibration:

• Under Review less than 4 weeks: Reviewers may still be confirming or starting reports. No read.
• 4-8 weeks: Reports often arrive in this window.
• 8-12 weeks: Decision is imminent if reports are in.
• 12+ weeks: Reviewer recruitment difficulty or split reviewer opinions. Inquiry appropriate.

Wait at least 12-14 weeks from submission before contacting the BMC Medicine editorial office. When you do:

• Use the Editorial Manager messaging system or email the contact listed in your submission confirmation
• Reference your manuscript ID
• Keep the message brief: request a status update, note when you submitted

One follow-up per 4-week interval after the 14-week mark is reasonable. The editorial office can prompt unresponsive reviewers but cannot bypass them. For specialized clinical topics, the office may explain the delay and provide an updated estimate.

• Reject: Usually with reviewer comments. BMC Medicine editors weigh reviewer judgment heavily; a clean reject typically reflects substantive methodological or scope objections.
• Major revision: Most common at BMC Medicine. Expect requests to clarify methods, expand limitations, complete reporting checklists thoroughly, or address specific reviewer questions.
• Minor revision: Common for well-prepared manuscripts; usually 2-4 weeks turnaround for the second round.
• Accept: Possible but uncommon as a first response.

Before submitting a revision with significant new analyses, a BMC Medicine submission readiness check can assess whether the response addresses the reviewers' core methodological concerns.

Of the medical research manuscripts our team reviewed before BMC Medicine submission, three named rejection patterns account for the bulk of editorial returns. Editors at BMC Medicine consistently reject papers on these three patterns within the 1-2 week initial screen, and SciRev community data for BMC Medicine aligns with what we observe in our internal analysis. The hidden filter authors most often miss is whether the paper reads as broad-relevance medicine or specialty medicine. Editorial culture at BMC Medicine demands that the public-health or general-medicine relevance be explicit and the reporting-checklist compliance be complete.

Reporting checklists completed with "see Methods" instead of specific page citations. BMC Medicine, like the broader BMC Series, requires that reporting checklists (CONSORT, PRISMA, STROBE, ARRIVE) be completed with item-by-item references to specific page numbers and section headings. We observe that papers completing checklists with generic "see Methods" or "N/A" entries generate editorial returns at the initial-screen stage. BMC Medicine editors check this routinely before assigning reviewers. Papers that map each checklist item to a specific page clear this screen and move directly to peer review.

Data availability statements that say "available on reasonable request". BMC Medicine's data availability policy requires that data be actually available, not conditionally available on author discretion. We see this routinely in submissions: authors include "data available from the corresponding author on reasonable request" because their institutional or funder agreement does not require full deposit. BMC Medicine editors flag this and request that authors either deposit the data in a public repository (where ethics permits) or explain in detail why data cannot be shared. Papers that proactively address data availability with a deposit URL, repository identifier, or detailed restriction explanation move faster.

Manuscripts framed for a sub-specialty audience without broader medical relevance. BMC Medicine's scope is broad medicine: papers should be relevant to general physicians, public-health practitioners, or health-systems researchers, not only to a narrow sub-specialty. We observe that authors with strong sub-specialty papers (e.g., niche oncology subtypes, rare neurological conditions, specialty-specific surgical techniques) target BMC Medicine because of its broad readership and high impact factor, but the editors redirect these papers to BMC sub-specialty journals (BMC Cancer, BMC Neurology, BMC Surgery). The redirect adds 2-4 weeks to the cycle. A BMC Medicine submission readiness check can identify whether the paper's broad-medicine relevance is sufficient before submission.